Portfolio Category: Pharmaceuticals

MEDPNC focuses on predicting efficient personalized drug combinations for the treatment of individual cancer patients, according to their altered protein network structure. Targeting key proteins maintaining the activity of individualized altered networks facilitates the efficient design of personalized treatments that will improve patient survival. The reduction of multiple variable datasets to a small number of physical parameters allows MEDPNC to predict the direction of change in biological, including pathological, systems, thereby generating rationalized treatment strategies through the manipulation of specific phenotypes.

We at CardioVia provide the physicians with a minimal invasive access capability to the heart through the pericardium in order to treat the most prevalent Cardiovascular Diseases and arrhythmias without using a needle. ​The CardioVia device includes a delivery device that allows controlled and measured progress; CardioVia will Automatically identify and halt at the entrance of the pericardium using the bioimpedance sensor. 

Spero Biopharma Ltd. was founded by Prof. Marta Weinstock-Rosin, a world renowned researcher of Alzheimer disease. Prof. Weinstock-Rosin is the inventor of Exelon®, a blockbuster drug for the treatment of Alzheimer’s disease, and a professor emeritus at the Hebrew University’s School of Pharmacy-Institute for Drug Research in the Faculty of Medicine.

SyndromeX is a pharmaceutical company that develops drugs for metabolic syndrome and related diseases such as dyslipidemia, type-2 diabetes, obesity, hypertension, and atherosclerotic cardiovascular disease. In an effort to keep metabolic syndrome patients from having to take five to eight different drugs, SyndromeX aims to develop an all-in-one therapy for the disorder and its component diseases.

PsyRx is a pharmaceutical R&D company facilitating, for the first time, biological API Psilocybin and Ibogaine at consistent quality to GMP standard in order to: utilize biological bioreactor technology to become a leading producer of GMP standard Ibogaine and Psilocybin to be used by target customers in the development and production of psychedelic and Ibogaine-based products, including pharmaceuticals, food supplements and others. Develop a revolutionary anti-depressant drug based on the combination of Ibogaine with existing approved antidepressants with a view to reducing side effect and generally improve efficacy.

Immunyx is a drug development company focused on modulating neutrophil function to treat disease. Numerous high burden illnesses such as COPD, cancer, and arthritis involve deregulated neutrophils which exacerbate and sometimes cause the underlying pathology. Using our platform technology to specifically manipulate neutrophils using a targeted nanoparticle, Immunyx will bring new therapies to several diseases where neutrophil treatment could advance a cure. Currently there are no FDA approved drugs targeting neutrophil activity in disease, providing Immunyx the potential to provide first in class therapies for a variety of diseases.

Nexocarp offers novel micro-encapsulation solutions in liquid and powder formulas to accelerate the sustainable transformation of products. All industries, especially Agriculture and Food-Tech will benefit from these long-lasting safe solutions which also safeguard the environment.